Phillip Allen Sharp (born June 6, 1944) is an American geneticist and molecular biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in ...
Us Patents
Nuclear Factors Associated With Transcriptional Regulation
David Baltimore - New York NY Ranjan Sen - Cambridge MA Phillip A. Sharp - Newton MA Harinder Singh - Chicago IL Louis Staudt - Silver Springs MD Jonathan H. Lebowitz - Zionsville IN Roger G. Clerc - Binningen, CH Lynn M. Corcoran - Port Melbourne, AU Patrick A. Baeuerle - Eichenau, DE Michael J. Lenardo - Potomac MD Chen-Ming Fan - San Francisco MA Thomas P. Maniatis - Belmont MA
Assignee:
President Fellows of Harvard College - Cambridge MA Massachusetts Institute of Technology - Cambridge MA Whitehead Instittue for Biomedical Research - Cambridge MA
Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
Nuclear Factors Associated With Transcriptional Regulation
David Baltimore - New York NY, US Ranjan Sen - Cambridge MA, US Phillip Sharp - Newton MA, US Harinder Singh - Chicago IL, US Louis Staudt - Silver Springs MD, US Jonathan LeBowitz - Zionsville IN, US Albert Baldwin - Chapel Hill NC, US Roger Clerc - Binningen, CH Lynn Corcoran - Port Melbourne, AU Patrick Baeuerle - Eichenau, DE Michael Lenardo - Potomac MD, US Chen-Ming Fan - San Francisco MA, US Thomas Maniatis - Belmont MA, US
International Classification:
C07K014/47 C07H021/04
US Classification:
514/012000, 530/358000, 536/023500
Abstract:
Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
Nuclear Factors Associated With Transcriptional Regulation
David Baltimore - New York NY, US Ranjan Sen - Cambridge MA, US Phillip Sharp - Newton MA, US Harinder Singh - Chicago IL, US Louis Staudt - Silver Springs MD, US Jonathan LeBowitz - Zionsville, IN Albert Baldwin - Chapel Hill NC, US Roger Clerc - Binningen, CH Lynn Corcoran - Port Melbourne, AU Patrick Baeuerle - Eichenau, DE Michael Lenardo - Potomac MD, US Chen-Ming Fan - San Francisco CA, US Thomas Maniatis - Belmont CA, US
International Classification:
A61K 38/17 C07K 14/47 C07H 21/04
US Classification:
514012000, 530358000, 536023500
Abstract:
Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.
Rna Sequence-Specific Mediators Of Rna Interference
Thomas Tuschl - New York NY, US Phillip Zamore - Northborough MA, US Phillip Sharp - Newton MA, US David Bartel - Brookline MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Massachusetts Institute of Technology - Cambridge MA University of Massachusetts Medical Center - Worcester MA Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V. - Munich
International Classification:
C12Q 1/68 A01K 67/033 C12N 1/21 C12N 5/06
US Classification:
435006000, 435325000, 435252300, 800008000
Abstract:
The present invention relates to a in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
Rna Sequence-Specific Mediators Of Rna Interference
Thomas Tuschl - New York NY, US Phillip Zamore - Northborough MA, US Phillip Sharp - Newton MA, US David Bartel - Brookline MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Massachusetts Institute of Technology - Cambridge MA University of Massachusetts Medical Center - Worcester MA Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V. - Munich
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention relates to a in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
Rna Sequence-Specific Mediators Of Rna Interference
Thomas Tuschl - New York NY, US Phillip Zamore - Northborough MA, US Phillip Sharp - Newton MA, US David Bartel - Brookline MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Massachusetts Institute of Technology - Cambridge MA University of Massachusetts Medical Center - Worcester MA Max-Planck-Gesellschaft zur Forderug der Wissenschaften E. V. - Munich
International Classification:
C12Q 1/68 C07H 21/02 C12P 19/34
US Classification:
435006000, 435091200, 536023100
Abstract:
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
Rna Sequence-Specific Mediators Of Rna Interference
Thomas Tuschl - New York NY, US Phillip Zamore - Northborough MA, US Phillip Sharp - Newton MA, US David Bartel - Brookline MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Massachusetts Institute of Technology - Cambridge MA University of Massachusetts Medical Center - Worcester MA Max-Planck-Gesellschaft zur Forderug der Wissenschaften E.V. - Munich
International Classification:
C12Q 1/68 C12N 15/86
US Classification:
435006000, 435456000
Abstract:
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene finction. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
Rna Sequence-Specific Mediators Of Rna Interference
Thomas Tuschi - New York NY, US Phillip D. Zamore - Northborough MA, US Phillip A. Sharp - Newton MA, US David P. Bartel - Brookline MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Massachusetts Institute of Technology - Cambridge MA University of Massachusetts Medical Center - Worcester MA Max-Planck-Gesellschaft zur Forderung der - Munich
International Classification:
A61K 31/70 C12N 15/87 A61P 43/00 C12N 15/01
US Classification:
514 44, 435463, 435441
Abstract:
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
I am a future member of the USMC, I am currently in my last year of high school, but I have completed the USMC boot camp and I do intend to enter my enlistment after college and go in as an officer.
Robert Robert, Sondra Kelly, Joyce Jenkins, Gerald Randles, Kenneth Souther, Dona Gurtler, Donna Nelson, Virgil Blackman, Bobbie Erwin, Dick Rodriguez, Otis Freeman, Viola James
Although California has a strong venture-capital presence, too, the big difference for the Boston area is the presence of leading pharmaceutical companies many of which are just a walk from the Massachusetts Institute of Technology (MIT) and Harvard, says Nobel laureate Phillip Sharp, who holds
Date: Nov 20, 2024
Category: Your local news
Source: Google
MIT developing framework for Covid-19 vaccinations on campus
I plan to be vaccinated assoon I can, and I am urgingeveryone at MIT and well beyond to get themselves vaccinated at theirfirst opportunity, says Institute Professor and Nobel laureate Phillip Sharp, whose pioneering research in the 1970s helped pave the way for todays generation of mRNA vacci
an abnormal expression of several important genes in the cartilaginous growth plates and the ends of the long tubular bones. These studies were done in collaboration with Hiroshi Suzuki, researcher at the Massachusetts Institute of Technology in the lab of Phillip Sharp, Nobel laureate in medicine.
Date: Feb 25, 2019
Category: Headlines
Source: Google
Local scientists worry about NIH's proposed cap on funding for individual labs
point system could penalize work done under multi-institutional NIH grants that involve researchers from multiple labs, often in the Boston area. Science in Massachusetts is done in a collaborative mode where researchers share data and expertise, said Phillip Sharp, a co-founder of Biogen Inc. who
Date: Jun 07, 2017
Category: Health
Source: Google
From basic research to saving lives — the Spinraza story
In the spring of 1977, Drs. Richard Roberts of CSHL and Phillip Sharp, then of MIT, first described RNA splicing a fundamental mechanism in cells that regulates how our genes are expressed, Stillman said.
Date: Dec 26, 2016
Category: Health
Source: Google
107 Nobel laureates sign letter blasting Greenpeace over GMOs
The letter campaign was organized by Richard Roberts, chief scientific officer of New England Biolabs and, with Phillip Sharp, the winner of the 1993 Nobel Prize in physiology or medicine for the discovery of genetic sequences known as introns. The campaign has a website, supportprecisionagriculture
Date: Jun 29, 2016
Category: Business
Source: Google
Cells Read DNA Backward and Forward: Direction is the Key
"This is part of an RNA revolution where we're seeing different RNAs and new RNAs that we hadn't suspected were present in cells, and trying to understand what role they have in the health of the cell or the viability of the cell," said Phillip Sharp, one of the MIT researchers who worked on the stu
Date: Jun 25, 2013
Category: Sci/Tech
Source: Google
Study Elucidates How Cells Make Sense of Transcriptional Direction
MITs Phillip Sharp, Ph.D., and his colleagues this week show that, in murine embryonic stem cells, asymmetric sequence determinants flanking gene transcription start sites control promoter directionality by regulating promoter-proximal cleavage and polyadenylation. Writing in Nature, Dr. Sharps